In the News
BIO 2022: Push to model disease biology advancing, but slowly
Big pharma executives and an academic ex- pert weighing the challenge at the BIO International Convention said June 14 they see another tool slowly gaining traction with the potential to decrease timelines and boost chances for approval: in silico modeling.
read more
Scrip Asks…What Does 2022 Hold For Biopharma? Part 5: Clinical Trials
Industry leaders sharing their predictions around clinical development homed in on decentralized trials, digitization and data tools as key topics for 2022…
read more
12 Tech Trends To Watch Closely In 2022
For potentially life-saving drugs and treatments, the road to commercialization is steep. Virtualizing the clinical trial is listed as a tech trend to accelerate drugs discovery and development. As per CB Insights, “In silico techniques will cut the time and money it takes to develop a drug and insulate clinical trials from disruptions…
read moreEvents
Meet us at Precision Medicine World Conference – PMWC
We are delighted to attend PMWC annual meeting this year, the largest medicine conference in the world….
read more
Panel discussion at BIO “Why the FDA Will Bet More on in Silico Simulations To Trigger Better Success Rates for NDAs”
Don’t miss our panel at BIO, titled “Why the FDA Will Bet More on in Silico Simulations To Trigger Better Success Rates for NDAs”.
read more
Meet us at 2022 ASCO Annual Meeting
We are delighted to attend the 2022 ASCO Annual Meeting, the world’s leading professional organization for physicians and oncology professionals…
read morePress Releases
GNS Appoints John Maraganore, PhD, as Strategic Advisor
GNS today announced that John Maraganore, PhD, biopharma industry leader and the former founding CEO of Alnylam Pharmaceuticals, has joined GNS as a strategic advisor.
read moreGNS and the Global Alzheimer’s Platform Foundation® Partner to advance Alzheimer’s R&D
3-year partnership will leverage biomarker database and AI for innovation to create“Digital Twins” that help uncover the complex biology driving Alzheimer’s Disease
read moreGNS Healthcare and Arvinas Enter into Neuroscience Drug Discovery Collaboration
GNS Healthcare, today announced a collaboration with Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, to generate insights to help accelerate drug development for neurodegenerative diseases…
read more